We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Rheumatoid Arthritis-Associated Interstitial Lung Disease: Characterization of Lung Disease Progression (BERTHA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04136223
Recruitment Status : Active, not recruiting
First Posted : October 23, 2019
Last Update Posted : August 9, 2022
Bristol-Myers Squibb
Information provided by (Responsible Party):
Hospital do Coracao

Brief Summary:
BERTHA study´s primary objective is to characterize Rheumatoid Arthritis-associated Interstitial Lung Disease (RA-ILD) progression and to define a combination of biomarkers, genetic and clinical variables capable of identifying patients at risk of RA-ILD progression

Condition or disease
Rheumatoid Lung Rheumatoid Arthritis Interstitial Lung Disease Pulmonary Fibrosis

Detailed Description:

BERTHA is a multicentric, observational study that will enroll 100 RA-ILD patients to be followed for 2 years.

Interstitial Lung Disease (ILD) progression will be ascertained by quantitative image analysis and functional parameters. Variables associated with progression with be identified.

Additionally, RA-ILD endotypes will be investigated as well as their association with RA-ILD progression.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: BERTHA Study: Rheumatoid Arthritis-Associated Interstitial Lung Disease: Characterization of Lung Disease Progression. A Multicenter, Observational Study
Actual Study Start Date : March 1, 2021
Estimated Primary Completion Date : May 31, 2024
Estimated Study Completion Date : May 31, 2024


Consecutive adult patients (aged >18 years) with RA* and interstitial lung disease

*in accordance with the American College of Rheumatology (ACR) classification criteria of 2010

Primary Outcome Measures :
  1. Interstitial Lung Disease progression - FVC [ Time Frame: 2 years ]
    FVC longitudinal behavior (continuous variable)

Secondary Outcome Measures :
  1. Interstitial Lung Disease progression - imaging [ Time Frame: 2 years ]
    quantitative overall disease progression (continuous variable) & %VRS (vessel related structures) > 4.4% if access to CALIPER software

  2. Interstitial Lung Disease progression - death [ Time Frame: 2 years ]
    Time to death or lung transplant

  3. Interstitial Lung Disease progression - FVC dichotomous variable [ Time Frame: 2 years ]

    Proportion of patients with a change from baseline in the %Forced Vital Capacity (FVC):

    1. greater or equal to 10% or
    2. between 5 and 10% and worsening of symptoms

Biospecimen Retention:   Samples With DNA
Blood samples

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
RA-ILD patients defined by altered imaging and associated functional derangements and/ or symptoms

Inclusion Criteria:

  1. Consecutive adult patients (aged >18 years) meeting RA diagnostic criteria in accordance with ACR 2010
  2. Presence of interstitial lung disease 2.1 ILD Definition: presence of interstitial alterations in HRCT associated to functional derangements and/or symptoms
  3. Patient agrees with having follow-up visits every 6 months for 2 years

Exclusion Criteria:

  1. Pregnancy or intending to become pregnant
  2. Overlap with other diseases that occurs with ILD (other collagenoses, vasculitis, inflammatory bowel disease)
  3. Presence of advanced ILD, characterized by:

    a. Dyspnea rated as modified Medical Research Council 4 (mMRC4) on routine visit

  4. Presence of significant Arterial Pulmonary Hypertension:

    1. Evidence of Right ventricular failure evidence by echocardiography
    2. Previous right chamber catheterism showing cardiac index < 2 liters/min/m²
  5. Significant co-morbidity impacting respiratory system (e.g., congestive heart failure, lung neoplasm, active tuberculosis)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04136223

Layout table for location information
Hospital Universitário de Brasilia (HUB)
Brasília, DF, Brazil, 70840-901
Hospital das Clinicas - FMUSP
Sao Paulo, SP, Brazil, 05403-000
Universidade Estadual de Campinas (UNICAMP)
Campinas, Brazil
LABOX - Federal University of Santa Catarina (UFSC)
Florianopolis, Brazil
LAPOGE - Federal University of Santa Catarina (UFSC)
Florianopolis, Brazil
Sponsors and Collaborators
Hospital do Coracao
Bristol-Myers Squibb
Layout table for investigator information
Study Chair: Prof. Alexandra Latini, PhD Federal University of Santa Catarina
Study Chair: Leticia Kawano-Dourado, MD HCOR Research Institute, Hospital do Coracao, São Paulo, Brazil
Layout table for additonal information
Responsible Party: Hospital do Coracao
ClinicalTrials.gov Identifier: NCT04136223    
Other Study ID Numbers: BERTHA_IM101-839
First Posted: October 23, 2019    Key Record Dates
Last Update Posted: August 9, 2022
Last Verified: August 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Under development
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Analytic Code

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis, Rheumatoid
Lung Diseases
Pulmonary Fibrosis
Lung Diseases, Interstitial
Disease Progression
Joint Diseases
Musculoskeletal Diseases
Pathologic Processes
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Respiratory Tract Diseases
Disease Attributes